Author: jezzabellemente

^{The Nature Conservancy and Mary Kay Inc. announced their partnership in 1990. Mary Kay has continued to generously support TNC’s work with an expanded focus on oceans work around the globe. (Credit: The Nature Conservancy)}

DALLAS, Nov 11 (Bernama-BUSINESS WIRE) — Throughout 2022, Mary Kay Inc., a global advocate for corporate sustainability and stewardship, has worked to elevate ocean awareness in climate work and as an approach to address the climate crisis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221110005014/en/

This month, Mary Kay was recognized in The Nature Conservancy’s 2022 Global Reefs Impact Report. The Nature Conservancy’s report highlights their recent achievements and how the organization has partnered with the private sector to successfully implement innovative marine conservation programs that protect and preserve life in our oceans.

The report showcased a newly launched project focused on “Super Reefs.” Super Reefs are highly resilient and can survive in a warming ocean. The mission of the Super Reefs project is to identify, protect, and grow a global network of Super Reefs to secure the future of coral reefs. The Super Reefs team brings together experts in ocean science, conservation, and management from Woods Hole Oceanographic Institution, Stanford University, and The Nature Conservancy, along with private sector support from Mary Kay, to support governments and communities at this critical moment in the history of coral reefs.

“I’ve seen reefs that have been destroyed, and I’ve seen reefs that have bounced back in my lifetime,” says Elizabeth McLeod, Global Reefs Systems Lead at The Nature Conservancy. “We have an imperative to get out in the water, to identify coral reefs that can survive climate change and ensure that they are protected from other impacts.”

“Our partnership with The Nature Conservancy stretches back more than 32 years—but we’re just getting started,” said Deborah Gibbins, Chief Operation Officer for Mary Kay Inc. “Throughout 2022, we’ve doubled down on our sustainability efforts, including a focus on ocean health. The health of our oceans is the health of our planet, and it’s essential we do our part to protect them.”

In 2022, Mary Kay supported 11 projects related to global ocean protection initiatives to improve ocean health for nature and people through the protection and restoration of critical habitats such as coral reefs, oyster reefs, and coastal wetlands. These important projects included:

• Restoring Asia Pacific shellfish reefs in Australia, Hong Kong, China, and the Coral Triangle;
• Ensuring that coral protection and restoration efforts in the Coral Triangle countries – Indonesia, Papua New Guinea, and the Solomon Islands – are supported through conservation efforts and initiatives that positively impact the whole region;
• Supporting women environmental leaders in the Pacific in Papua New Guinea and the Solomon Islands;
• Coastal conservation and restoration in the Gulf Coast and assessing the feasibility of blue carbon markets to support long-term wetland management; and
• Improving fisheries in Mexico to empower communities and women in the fishing industry.

To read more about Mary Kay’s commitment to sustainability, visit marykayglobal.com/sustainability and download Mary Kay’s global sustainability strategy: Enriching Lives Today for a Sustainable Tomorrow.

About The Nature Conservancy (TNC)

The Nature Conservancy is a global conservation organization dedicated to conserving the lands and waters on which all life depends. Guided by science, we create innovative, on-the-ground solutions to our world’s toughest challenges so that nature and people can thrive together. We are tackling climate change, conserving lands, waters, and oceans at an unprecedented scale, providing food and water sustainably, and helping make cities more sustainable. Working in 79 countries and territories, we use a collaborative approach that engages local communities, governments, the private sector, and other partners. To learn more, visit www.nature.org or follow @nature_press on Twitter.

About Mary Kay Inc.

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors of domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20221110005014/en/

Contact

Mary Kay Inc.
Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

The Nature Conservancy
Misty Edgecomb
Communications Director
medgecomb@tnc.org or 484-343-3223

Source : Mary Kay Inc.

KUALA LUMPUR, Nov 11 (Bernama) — Adagene Inc (Adagene) has announced clinical data from phase 1b/2 studies of its anti-CTLA-4 antibody candidate, ADG116, in two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in Boston.

Acording to a statement, the first poster reviewed data from an open label, phase 1b/2 dose escalation and dose expansion trial evaluating ADG116 as monotherapy and in combination with toripalimab in heavily pre-treated patients with advanced metastatic solid tumours.

The poster is titled “A Phase 1b/2 Study of a Novel Anti-CTLA-4 NEObody™ ADG116 Monotherapy and in Combination with Toripalimab (Tori; Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors”.

Key findings as of the data cutoff date on Sept 19, 2022, include compelling, differentiated safety profile demonstrated with ADG116 monotherapy up to 15 mg/kg; and monotherapy efficacy shown in heavily pre-treated patients.

Meanwhile, findings from a second poster, “A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of an Anti-CTLA-4 NEObody™ ADG116 in Combination with Pembrolizumab (Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors: A Preliminary Update”, established a safe and potentially active dose level for ADG116 in combination with pembrolizumab.

“These data provide compelling clinical evidence for our unique approach to targeting a distinct and highly conserved epitope of CTLA-4 with NEObody ADG116 to achieve enhanced anti-CTLA-4 blockade for both improved efficacy and safety profiles in single agent and combination settings, when combined with two different anti-PD-1 therapies,” said Co-founder, Chief Executive Officer and Chairman of Adagene, Peter Luo, Ph.D.

Adagene Inc is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.

More details at https://investor.adagene.com.

— BERNAMA

^{The press conference’s carbon footprint is offset by the carbon credits issued by the VCS program, making it Singapore’s first “Zero Carbon Conference”. (Photo: Business Wire)}

SINGAPORE, Nov 7 (Bernama-BUSINESS WIRE) — Zero Carbon Future Private Limited, the most active carbon market in Asia, launched the Zero Carbon EX platform on November 5^th, 2022 in Singapore.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221106005063/en/

The platform, a promising one to be the largest carbon trading platform in Asia-Pacific region, will accelerate the globalization of Zero Carbon Future Pte Ltd and contribute to the global warming mitigation work.

The Zero Carbon EX platform, developed and operated by Singapore Zero Future Pte Ltd, is a PaaS (Platform-as-a-Service) one-stop service platform specializing in the carbon neutral related, carbon asset management business. The platform provides carbon credit development, carbon asset custody, carbon emission accounting, carbon neutrality consulting and other zero carbon products, contributing to the zero carbon actions.

What is worth mentioning here is that the press conference today is offset by carbon credits issued by the VCS program, making it a “Zero Carbon Conference”.

Jonathan Yap, CEO of Northwaters Capital Pte Ltd, said after introducing Northwaters Capital’s business scope and social impact, “We have launched the Carbon Assets Global Opportunity Fund to invest in carbon credit assets around the world. Northwaters Capital is well positioned to identify advanced climate technology projects in carbon neutrality and to facilitate the commercialization of these projects in Asia-Pacific region and other carbon neutral related businesses. We are delighted to work with Zero Carbon Future Pte Ltd to promote the development and expansion of the global carbon credit market. Asia’s carbon markets present both exciting possibilities and challenges. In the future, we believe we can become a leader in this field to support the growth of carbon markets and the development of green technologies in Asia.”

Northwaters Capital Phase I Fund has successfully purchased 2 million tons of VCS carbon assets, becoming the largest carbon asset management company in Asia-Pacific region.

At the launching ceremony, Northwaters Capital Pte Ltd and Zero Carbon Future Pte Ltd signed a custodian agreement of 2 million tons of VCS carbon assets to be managed on the Zero Carbon EX platform.

Dr. Bangdao Chen, CEO of Zero Carbon Future Pte Ltd, introduced the background of the launch and the application scenarios of the Zero Carbon EX platform in detail, “It is committed to building a Web3 digital asset standard and green finance system for the purpose of carbon neutral and environmental protection. The Zero Carbon EX platform will build a new green financial ecology to reduce carbon asset market barriers to entry, and enable more individuals, businesses and government to accept the carbon neutral concept and configure carbon assets by providing a safe and easy-to-use carbon asset account service. In future, everyone will have a ‘carbon’ account and a ‘carbon’ purse, combining daily life with carbon neutral. Through the trading and flow of ‘green’ digital currency based on carbon assets, countries around the world will be linked into a network to accelerate the process of global carbon peak and carbon neutrality.”

Wu Guoliang, Chairman of the ASEAN Strategic Committee of China Carbon Neutral Group, said, “We provide a one-stop carbon neutral solution that powers carbon credit asset development, production and investment services for enterprises, governments and individuals, engaging in carbon neutral business on a global scale leveraging the complementary and synergistic effects of carbon finance and carbon technology. Today, we are here to witness the launch of the Zero Carbon EX platform, resulting in a business partnership between Northwaters Capital and Zero Carbon Future, with two million tons of VCS carbon credits under escrow, which is part of an effort of the trading markets for carbon credits to support the sustainability of decarbonization. With Singapore as a regional gateway for carbon services, it is expected to facilitate the development of Singapore’s carbon services ecosystem by working with more international companies.”

About 30 guests and journalists, including Jonathan Yap, CEO of Northwaters Capital Pte Ltd, and Professor Bill Roscoe, Chief Scientist Advisor of Zero Carbon Future Pte Ltd, attended the launch ceremony of the Zero Carbon EX platform.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20221106005063/en/

Contact

Zero Carbon Future Pte Ltd
006588185333
ir@zerocarbonfuture.ltd

Source : Zero Carbon Future Private Limited

KUALA LUMPUR, Nov 2 (Bernama) — American Express Travel has published the 2023 Trending Destinations list, featuring the 10 most popular destinations for travel next year, identified by global American Express Card Member travel reservations.

The destinations are Copenhagen; Florida Keys; Istanbul; Lisbon; Mexico City; Montenegro; Paris, Sydney; Woodstock; and Fiji’s Yaukuve Island.

In a statement, it said American Express Travel Consultants also created three-day itineraries for each of these destinations, providing inspiration on the top places to stay, eat, shop and explore the local culture.

This includes how Platinum card members can spend the “bonus vacation day” they receive with a guaranteed 4pm check-out when they book a Fine Hotels + Resort property through American Express Travel.

“When card members book trips through American Express Travel, they are trusting us with their most valuable resource, their time.

“Our global footprint, over 100 years of travel expertise and deep understanding of our card members, give us a unique ability to inspire travellers with this year’s list of Trending Destinations, make the planning process easy, and confidently advise them on what to do when they get there,” said American Express Travel president, Audrey Hendley.

In addition to top destinations, American Express Travel has also identified key trends driving travel in 2023, including new adventures that are in demand, vacationing with holistic health in mind, and seeking out personalised experiences.

American Express Travel’s 2023 Trending Destinations are selected based on global American Express card member bookings through American Express Travel, looking at year-over-year travel growth between 2019 and 2022.

American Express is a globally integrated payments company, providing customers with access to products, insights and experiences that enrich lives and build business success.

— BERNAMA

New data from clinical trials of TT11 and TT11X to be featured in two oral podium presentations and a poster presentation

SINGAPORE, Nov 4 (Bernama-GLOBE NEWSWIRE) — Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that three abstracts reporting data from clinical trials investigating the company’s autologous CD30.CAR-T therapy (TT11) and allogeneic CD30.CAR EBVST therapy (TT11X) have been accepted for presentation at the 64^th American Society of Hematology Annual Meeting (ASH 2022) taking place December 10-13, 2022, at the Ernest N. Morial Convention Center in New Orleans.

TT11, Tessa’s lead clinical asset, is an autologous CD30.CAR-T therapy currently being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma (r/r cHL) as both a monotherapy (Phase 2 CHARIOT) and combination therapy (Phase 1b). Two abstracts involving updated data from the CHARIOT clinical trial will be presented at ASH 2022, including an oral podium presentation demonstrating that circulating tumor DNA (ctDNA) analysis with Foresight Diagnostics PhasED-Seq technology provides a viable biomarker to monitor responses, rapidly stratify risk, and predict outcomes of r/r cHL patients treated with TT11.

TT11X, Tessa’s allogeneic “off-the-shelf” cell therapy, is based on Tessa’s proprietary CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) platform. An abstract highlighting updated data from the ongoing Phase 1/2 study of TT11X (BESTA) in CD30-positive lymphomas will be featured in an oral podium presentation at ASH 2022. The research demonstrates CD30.CAR EBVSTs (TT11X) to be a well-tolerated and preliminary efficacious treatment for CD30+ lymphomas.

“We are honored that ASH has accepted three abstracts involving Tessa’s autologous and allogeneic CD30.CAR-T therapies, including two oral podium presentations, at its prestigious annual meeting,” stated Thomas Willemsen, President and CEO of Tessa Therapeutics. “The data being presented at ASH 2022 from the ongoing clinical trials of TT11 and TT11X demonstrate the potential of these therapies to safely and effectively treat CD30 positive lymphomas, including relapsed or refractory classical Hodgkin lymphoma. ASH is an ideal venue for highlighting this important research, and we are grateful to the investigators at the Baylor College of Medicine, Stanford University and MD Anderson Cancer Center for leading their respective presentations.”

Abstract Number: 167 (Podium)
Abstract Title: CD30.CAR-modified Epstein-Barr Virus-specific T-cells (CD30.CAR EBVST’s) Provide a Safe and Effective Off-The-Shelf Therapy for Patients with CD30-Positive Lymphoma (BESTA)
Presenting Author: David H. Quach, PhD, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX
Session Date: Saturday, Dec. 10, 2022, at 1:00 PM CT; Ballroom AB
Abstract Summary:
Off-the-shelf allogeneic T-cell therapies face a major challenge of graft-versus-host disease (GVHD) and graft rejection mediated by host and recipient alloreactive T-cells, respectively. Epstein-Barr-specific T cells (EBVSTs), which are virus-specific rather than allo-specific, offer the potential to mitigate GVHD, and data thus far from more than 300 allogeneic recipients have not produced GVHD. An analysis from an ongoing Phase 1/2 clinical trial of CD30.CAR EBVSTs in patients with CD30-positive lymphoma has demonstrated the therapy to be a well-tolerated and preliminary efficacious treatment for CD30+ lymphomas and may avert GVHD and immediate rejection even after multiple infusions.

Abstract Number: 3338 (Poster)
Abstract Title:  Updated Results and Correlative Analysis of CHARIOT Trial: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
Presenting Author: Sairah Ahmed, MD., Department of Lymphoma/Myeloma and Stem Cell Transplantation, MD Anderson Cancer Center, Houston, TX
Session Date: Sunday, Dec. 11, 6:00 PM-8:00 PM CT; Hall D
Abstract Summary:
Early results from the pilot segment of a Phase 2 trial of autologous CD30.CAR-T in patients with relapsed/refractory (r/r) classic Hodgkin Lymphoma (cHL) demonstrated a favorable safety profile and excellent anti-tumor responses of CD30.CAR-T. In an updated clinical and exploratory biomarker analysis, the therapy is shown to be well tolerated with no unexpected safety signal. Additionally, data suggest strong anti-tumor efficacy with an overall response rate of 73.3% in heavily pretreated r/r cHL patients, as well as good expansion and persistence after infusion.

Abstract Number: 984 (Podium)
Abstract Title: Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T-Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)
Presenting Author: David M. Kurtz, MD, Ph.D., Stanford University, Stanford, CA.
Session Date: Monday, Dec. 12, 2022, 5:45 PM CT; Hall E
Abstract Summary:
CHARIOT, a Phase 2 single-arm, multicenter study, is designed to investigate the safety and efficacy of CD30.CAR-T cells in cHL patients experiencing progression after at least 3 lines of therapy. In the pilot part of the study, ctDNA was analyzed as an exploratory biomarker using Foresight Diagnostics PhasED-Seq MRD assay at multiple time points, including at baseline (pre-treatment), Day 42 post-CD30.CAR-T infusion (D42), and upon progressive disease (PD). Based on ctDNA successfully genotyped directly from pre-treatment plasma in 12 patients, it was determined that ctDNA responses largely mirrored radiographic responses, suggesting that pre-treatment ctDNA levels could have predictive value on patient response to CAR-T therapy. From this, the researchers concluded that PhasED-Seq ctDNA analysis is a viable biomarker to monitor responses, rapidly risk stratify, and predict outcomes of patients with r/r cHL treated with CD30.CAR-T therapy.

About Tessa Therapeutics 
Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors. Tessa’s lead clinical asset, TT11, is an autologous CD30-CAR-T therapy currently being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma as both a monotherapy (Phase 2) and combination therapy (Phase 1b). TT11 has been granted RMAT designation by the FDA and access to the PRIME scheme by European Medicine Agency. Tessa is also advancing an allogeneic “off-the-shelf” cell therapy platform targeting a broad range of cancers in which Epstein Barr Virus Specific T Cells (EBVSTs) are augmented with CD30-CAR. A therapy using this platform is currently the subject of a Phase 1 clinical trial in CD30-positive lymphomas. Tessa has its global headquarters in Singapore, where the company has built a state-of-the-art, commercial cell therapy manufacturing facility. For more information on Tessa, visit www.tessacell.com. 

Cautionary Note on Forward Looking Statements
This press release contains forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995, to the fullest extent applicable) including, without limitation, with respect to various regulatory filings or clinical study developments of the Company. You can identify these statements by the fact that they use words such as “anticipate,” “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, “may”, “assume” or similar expressions. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to the Company’s financial results, the ability to raise capital, dependence on strategic partnerships and licensees, the applicability of patents and proprietary technology, the timing for completion of the clinical trials of its product candidates, whether and when, if at all, the Company’s product candidates will receive marketing approval, and competition from other biopharmaceutical companies. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made, and disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The Company’s products are expressly for investigational use pursuant to a relevant investigational device exemption granted by the U.S. Food & Drug Administration, or equivalent competent body. 

Tessa Therapeutics Investor Contact

Wilson W. Cheung
Chief Financial Officer 
wcheung@tessacell.com

Tessa Therapeutics Media Contact

Tiberend Strategic Advisors, Inc.
Bill Borden
+1-732-910-1620 
bborden@tiberend.com

Dave Schemelia
+1-609-468-9325 
dschemelia@tiberend.com

SOURCE : Tessa Therapeutics Ltd